AUTO4

BIOLOGICAL2 trials

Conditions

Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPotential malignancy in patients who received treatment with Autolus CAR T cell therapy.T Cell Non-Hodgkin Lymphoma

Phase 1

Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

TerminatedNCT03590574

Autolus LimitedAnaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified +1

Start: 2018-08-30End: 2024-12-12Updated: 2026-03-16

Phase 2

Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.

RecruitingCTIS2024-511684-28-00

Autolus LimitedPotential malignancy in patients who received treatment with Autolus CAR T cell therapy.

Start: 2025-09-01Target: 21Updated: 2025-06-26

2024-11-1117 citations

FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA

Hematological Oncology2023-06-018 citations

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Blood2022-11-1526 citations

S261: SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A TRBC1-TARGETTING CAR, IN RELAPSED/REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA

HemaSphere2022-06-012 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

AUTO4

Sponsors

Conditions

Phase 1

Phase 2

Related Papers